We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Login or sign up: Please either login to Lexology or sign up for our free legal news service to be able to register for this event.

Excessive pricing in the pharmaceutical sector: recent European cases

Van Bael & Bellis


Description

  • What is the relevant legal test for excessive pricing under EU competition law?
  • What evidence do competition authorities examine?
  • Is there a risk that launch prices of innovative drugs will be deemed to be excessive?
  • How can you minimize your risk?

 

Speaker

David Hull is a partner in Van Bael & Bellis, a Brussels firm focused on EU competition and trade law. He is a seasoned competition lawyer, having started practising in Brussels in 1984. He specialises in representing clients in complex investigations before the European Commission, and in litigation before the EU courts in Luxembourg. Recent cases include Ryanair (appeal of commission’s decision blocking takeover of Aer Lingus); Akzo (legal privilege); Bitumen (appeal of fine imposed in cartel case); and Microsoft (appeal of fine imposed for alleged non-compliance with commission decision). 

Mr Hull has extensive experience in the life sciences sector, regularly representing companies in EU investigations and advising them on lifecycle management issues, European parallel trade and distribution issues (including co-marketing and co-promotion agreements), licensing and collaboration arrangements, pricing/discounting strategies and mergers. He is currently representing two companies before the European Court of Justice in the Lundbeck case on patent settlements. 

Mr Hull is admitted as a solicitor in England and Wales.

Speakers


David Hull

Details

Date
27 June 2018
Time
14:00 - 14:45 UTC
Duration
45 min
Language
English
Location
Online